profit from every $100 of sales.
$0$100
Regenxbio
$7.64-4.86% today
-34.4% in 1 year
1-year low $5.651-year high $15.98
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Regenxbio sold, what it kept, and what it did with the cash.
Sales went from $113 million in 2022 to $170 million in 2025, with -$194 million of profit last year.
SalesProfit
Regenxbio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Regenxbio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Regenxbio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 113 | 90 | 83 | 170 | |
| 58 | 53 | 50 | 150 | |
| -263 | -268 | -231 | -161 | |
| -244 | -239 | -198 | -133 | |
| -280 | -263 | -227 | -194 | |
| -6.50 | -6.02 | -4.59 | -3.76 | |
| 51.6% | 58.8% | 59.7% | 88.1% | |
| -233.2% | -297.1% | -277.5% | -94.6% | |
| -248.7% | -292.0% | -272.5% | -113.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 833 | 574 | 466 | 453 |
| Cash | 97 | 35 | 58 | 34 |
| Total debt | 95 | 89 | 82 | 74 |
| Total liabilities | 317 | 262 | 206 | 350 |
| 516 | 312 | 260 | 103 | |
| 43 | 44 | 50 | 52 | |
| -33.2% | -50.6% | -49.6% | -66.7% | |
| -54.3% | -84.5% | -87.5% | -188.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -207 | -218 | -173 | -124 | |
| 31 | 10 | 2 | 2 | |
| -238 | -228 | -176 | -126 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 41 | 40 | 38 | 35 |
Valuation
- –
- –
- –
- 14.1×
- 3.0×
- –
- –
- -25.0%
- -38.4%
- 0.0%
Profitability
- 88.1%
- -94.6%
- -113.8%
- -267.8%
- -92.1%
- -43.3%
- -232.5%
- -84.8%
- -94.8%
- 260.4%
Growth
- +14.8%
- –
- +28.0%
- –
- +5.0%
Financial health
- –
- 3.37
- 20.8%
- -9.3×
- 2.62
- 2.62
- 0.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 4%of 884
Top 37%of 886
Bottom 3%of 987
What analysts expect
- Average price target
- $25.75
- Range
- $12.00 – $45.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.72 | -1.36 | −26.5% |
| Mar 5, 2026 | -1.30 | -1.01 | −28.7% |
| Nov 6, 2025 | -1.20 | -1.38 | +13.0% |
| Aug 7, 2025 | -1.38 | -1.13 | −22.1% |
| May 12, 2025 | 0.12 | 0.41 | −70.7% |
| Mar 13, 2025 | -1.01 | -1.27 | +20.5% |
| Nov 6, 2024 | -1.17 | -1.16 | −0.9% |
| Aug 1, 2024 | -1.05 | -1.29 | +18.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
19No pass
Philip Fisher
41No pass
Peter Lynch
27No pass
Joel Greenblatt
2No pass
Charlie Munger
26No pass
Terry Smith
38No pass
Questions about Regenxbio
Is Regenxbio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Regenxbio AI analysis
What does Regenxbio do?
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. It is in Biotechnology.
Does Regenxbio pay a dividend?
No. Regenxbio does not pay a dividend at the moment.
Is Regenxbio stock halal?
Questionable. Regenxbio sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Regenxbio stock done over the past year?
Down 34.4% over the past twelve months, to $7.64. It traded between $5.65 and $15.98 and is 52.2% below its high.
Who are Regenxbio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Regenxbio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.